Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen.

Klose TS, Ibeanu GC, Ghanayem BI, Pedersen LG, Li L, Hall SD, Goldstein JA.

Arch Biochem Biophys. 1998 Sep 15;357(2):240-8.

PMID:
9735164
2.

Identification of human CYP2C19 residues that confer S-mephenytoin 4'-hydroxylation activity to CYP2C9.

Tsao CC, Wester MR, Ghanayem B, Coulter SJ, Chanas B, Johnson EF, Goldstein JA.

Biochemistry. 2001 Feb 20;40(7):1937-44.

PMID:
11329260
3.

Amino acid residues affecting the activities of human cytochrome P450 2C9 and 2C19.

Niwa T, Kageyama A, Kishimoto K, Yabusaki Y, Ishibashi F, Katagiri M.

Drug Metab Dispos. 2002 Aug;30(8):931-6.

4.

CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.

Wester MR, Lasker JM, Johnson EF, Raucy JL.

Drug Metab Dispos. 2000 Mar;28(3):354-9.

5.

Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.

Lasker JM, Wester MR, Aramsombatdee E, Raucy JL.

Arch Biochem Biophys. 1998 May 1;353(1):16-28.

PMID:
9578596
6.
7.
8.

Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding.

Haining RL, Jones JP, Henne KR, Fisher MB, Koop DR, Trager WF, Rettie AE.

Biochemistry. 1999 Mar 16;38(11):3285-92.

PMID:
10079071
9.

The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.

Gentile DM, Verhoeven CH, Shimada T, Back DJ.

J Pharmacol Exp Ther. 1998 Dec;287(3):975-82.

10.

Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.

Chang SY, Li W, Traeger SC, Wang B, Cui D, Zhang H, Wen B, Rodrigues AD.

Drug Metab Dispos. 2008 Dec;36(12):2513-22. doi: 10.1124/dmd.108.022970. Epub 2008 Sep 11.

11.
12.

The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.

Mamiya K, Ieiri I, Shimamoto J, Yukawa E, Imai J, Ninomiya H, Yamada H, Otsubo K, Higuchi S, Tashiro N.

Epilepsia. 1998 Dec;39(12):1317-23.

13.

Identification of residues 99, 220, and 221 of human cytochrome P450 2C19 as key determinants of omeprazole activity.

Ibeanu GC, Ghanayem BI, Linko P, Li L, Pederson LG, Goldstein JA.

J Biol Chem. 1996 May 24;271(21):12496-501.

14.

Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine.

Giancarlo GM, Venkatakrishnan K, Granda BW, von Moltke LL, Greenblatt DJ.

Eur J Clin Pharmacol. 2001 Apr;57(1):31-6.

PMID:
11372587
15.

Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.

Shon JH, Yoon YR, Kim KA, Lim YC, Lee KJ, Park JY, Cha IJ, Flockhart DA, Shin JG.

Pharmacogenetics. 2002 Mar;12(2):111-9.

PMID:
11875365
16.

Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.

Voorman RL, Payne NA, Wienkers LC, Hauer MJ, Sanders PE.

Drug Metab Dispos. 2001 Jan;29(1):41-7.

17.
18.

Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs.

Mancy A, Antignac M, Minoletti C, Dijols S, Mouries V, Duong NT, Battioni P, Dansette PM, Mansuy D.

Biochemistry. 1999 Oct 26;38(43):14264-70.

PMID:
10572000
19.
20.

Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily.

Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Miners JO, Rees DL, Gasser R, Meyer UA, Birkett DJ.

Biochem J. 1993 Jan 15;289 ( Pt 2):533-8.

Supplemental Content

Support Center